Compare Illumina, Inc. (ILMN) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Marvell Technology Inc — how do they compare? Illumina, Inc. trades at $189.99 (market cap $27.94B), while Marvell Technology Inc trades at $206 (market cap $171.11B). The key difference: Marvell Technology Inc is far larger — about 6.1× Illumina, Inc.'s market cap, and Marvell Technology Inc pays a 0.12% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | MRVL | |
|---|---|---|
Market Cap | $27.94B | $171.11B |
Sector | Health | Technology |
52-Week High | $194.33 | $316.43 |
52-Week Low | $91.00 | $62.31 |
Enterprise Value | $29.33B | $172.55B |
Dividend Yield | — | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Marvell Technology (MRVL) trades at $195.28, up 3.5% today, with a bullish technical signal from oscillators but bearish moving averages. Recent earnings have consistently beaten expectations, though the company reported a net loss of $885 million in 2025. Analyst consensus is strongly bullish with an average price target of $275.68, and the stock is positioned in the AI infrastructure sector, with news highlighting its potential in custom chips and networking.
Outlook is positive due to strong analyst support and AI-driven growth prospects, but risks include high valuation multiples, recent net losses, and semiconductor market volatility. The stock offers significant upside if execution matches expectations, yet investors must weigh growth potential against current profitability challenges and industry cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
